In this edition:
CARTITUDE-4: ciltacabtagene-autoleucel in RRMM
PHE885: a T-charge manufactured BCMA-directed CAR-T cell therapy for RRMM
GC012F: a novel dual-targeting CAR-T cell therapy for RRMM
Sequencing of bispecific antibodies/CAR-T cell therapy after exposure to BCMA-targeted therapies in MM
RedirecTT-1: combination teclistamab + talquetamab in RRMM
MajesTEC-1: switch from weekly to biweekly dosing of teclistamab in RRMM
MonumenTAL-1: talquetamab in RRMM
Elotuzumab-KRd arm vs. KRd in newly-diagnosed MM
Maintenance KPd in high-risk myeloma
Time to anti-resorptive therapy & skeletal related events in MM
Please login below to download this issue (PDF)